Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “sell” rating reaffirmed by equities research analysts at FBR & Co in a research report issued on Friday.
ALXN has been the subject of several other reports. Credit Suisse Group AG upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research report on Saturday, July 9th. Royal Bank Of Canada initiated coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 price target for the company. Leerink Swann upped their price objective on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a research note on Monday, September 26th. Cowen and Company reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, September 22nd. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $178.32.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.76% during midday trading on Friday, hitting $125.05. 1,009,863 shares of the company were exchanged. The firm’s 50 day moving average price is $127.95 and its 200 day moving average price is $134.91. The firm has a market capitalization of $28.04 billion, a price-to-earnings ratio of 314.20 and a beta of 1.33. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The business earned $753 million during the quarter, compared to analyst estimates of $743.18 million. During the same quarter last year, the company posted $1.44 earnings per share. The company’s revenue was up 18.4% compared to the same quarter last year. Analysts forecast that Alexion Pharmaceuticals will post $4.67 EPS for the current fiscal year.
In related news, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the completion of the sale, the director now owns 6,373 shares in the company, valued at $870,105.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Carsten Thiel sold 3,225 shares of the firm’s stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total transaction of $414,960.75. Following the sale, the executive vice president now owns 40,354 shares of the company’s stock, valued at approximately $5,192,349.18. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.
A number of hedge funds have recently bought and sold shares of ALXN. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals during the first quarter worth $114,000. NEXT Financial Group Inc raised its position in shares of Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC acquired a new position in shares of Alexion Pharmaceuticals during the second quarter worth $172,000. Charlemagne Capital Ltd. acquired a new position in shares of Alexion Pharmaceuticals during the second quarter worth $191,000. Finally, Evercore Wealth Management LLC raised its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares in the last quarter. Institutional investors and hedge funds own 96.34% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.